# Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

> **NCT06644417** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 122 (actual)

## Conditions studied

- HBV Infection With LLV

## Interventions

- **DRUG:** TQA3605 tablets plus NAs
- **DRUG:** TQA3605 Placebo plus NAs

## Key facts

- **NCT ID:** NCT06644417
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-14
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-12-10
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644417, "Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06644417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*